Opioid Withdrawal Syndrome Caused by Inappropriate Intrathecal Morphine-Fentanyl Conversion Ratio in a Scoliosis Patient: A Case Report

Technical Summary: Opioid Withdrawal Syndrome Caused by Inappropriate Intrathecal Morphine-Fentanyl Conversion Ratio

Problem Statement
Intrathecal drug delivery systems (IDDS) are a standard intervention for chronic refractory pain, with morphine being the primary FDA-approved agent. However, long-term morphine use often leads to tolerance, necessitating opioid rotation to alternative agents like fentanyl. While intravenous (IV) conversion ratios between morphine and fentanyl are well-established (typically 100:1), there is a critical lack of standardized, evidence-based guidelines for converting these agents specifically for intrathecal administration. The physicochemical differences between the two drugs—morphine's high water solubility and extensive cerebrospinal fluid (CSF) diffusion versus fentanyl's high lipophilicity and rapid CSF clearance—suggest that IV conversion ratios may be clinically inappropriate for intrathecal use. This uncertainty creates a significant risk of adverse events, specifically Opioid Withdrawal Syndrome (OWS), during the transition process.

Methodology and Case Presentation
This report details a single-case study of a 53-year-old male with congenital scoliosis and chronic right thoracodorsal neuropathic pain. The patient had achieved stable analgesia via an intrathecal morphine infusion (4.7977 mg/day) for nearly one year before developing tolerance.

The study followed a sequential titration protocol to manage the rotation from intrathecal morphine to fentanyl:

1. Initial Attempt: An initial conversion ratio of 200:1 (intrathecal morphine to fentanyl) was applied, reducing the morphine dose by 50% and doubling the fentanyl dose. This conservative approach was based on NCCN guidelines for reducing new opioid starting doses in tolerant patients.
2. Adverse Event: Within 24 hours, the patient developed moderate OWS (Clinical Opioid Withdrawal Scale [COWS] score of 14), characterized by tachycardia, diaphoresis, tremors, agitation, and worsening pain (NRS score increased from 6 to 8). Systemic oral oxycodone (40 mg/day) failed to resolve symptoms, highlighting the disparity between systemic and intrathecal potency.
3. Iterative Adjustment: The medical team systematically adjusted the conversion ratio and fentanyl dosage over 13 days:
   • Ratios were progressively lowered from 200:1 to 141.9:1, then 126:1, 100:1, 80:1, and 67.8:1.
   • Despite these adjustments, withdrawal symptoms persisted until the ratio reached 51:1.
4. Resolution: At the 51:1 conversion ratio (106.0910 µg/day fentanyl), the patient's withdrawal symptoms completely resolved (COWS score 0), and pain control improved significantly (NRS score decreased from 6 to 3).

Key Results

• Induction of Withdrawal: An overly conservative initial conversion ratio (200:1) precipitated moderate OWS, confirming that standard IV-derived safety reductions can be insufficient for intrathecal rotations.
• Inefficacy of Systemic Rescue: Oral opioid supplementation failed to mitigate intrathecal withdrawal, suggesting that management must prioritize adjusting the intrathecal infusion rather than systemic supplementation.
• Optimal Ratio Identification: Through stepwise titration, a conversion ratio of 51:1 was identified as effective for this specific patient, falling within the wide range (4:1 to 100:1) reported in existing literature but distinct from the commonly cited 100:1 IV benchmark.
• Symptom Profile: The withdrawal syndrome was dominated by central neurological and cardiovascular symptoms (tachycardia, tremor, agitation) without peripheral gastrointestinal signs, supporting the hypothesis that intrathecal OWS is a centrally mediated syndrome.

Key Contributions

• Documentation of a Specific Etiology: This is reported as the first case describing OWS induced specifically by an inappropriately conservative initial conversion ratio during intrathecal morphine-to-fentanyl rotation in a chronic non-cancer pain patient.
• Clinical Evidence for Individualization: The case provides empirical evidence that a single, universal conversion ratio for intrathecal opioids is unreliable. It demonstrates that anatomical factors (such as scoliosis) and individual pharmacokinetics necessitate dynamic, patient-specific titration.
• Management Strategy: The report outlines a successful clinical pathway for resolving intrathecal OWS: immediate cessation of the under-dosed regimen and progressive titration of the new opioid until the withdrawal syndrome resolves, rather than relying on systemic rescue medications.

Significance and Claims
The authors claim that this case underscores the inherent risks of intrathecal opioid rotation in the absence of standardized guidelines. The study emphasizes that clinicians must exercise extreme caution and prioritize individualized ratio titration and rigorous clinical monitoring. The findings suggest that the widely implemented 100:1 intrathecal conversion ratio (derived from systemic benchmarks) may be inappropriate for many patients, potentially leading to under-dosing and withdrawal. The paper concludes that further prospective, multicenter studies are required to establish evidence-based, individualized guidelines for intrathecal opioid conversion, particularly for patients with anatomical abnormalities.